1. Introduction {#sec1}
===============

Brunner\'s glands (BGs) are branched acinotubular glands and they are most common in the duodenal bulb \[[@B1]\]. Cruveilhier was the first to define BG adenomas in 1835 \[[@B1], [@B2]\]. In 1934, Feyrter classified these lesions as type 1 nodular hyperplasia, type 2 circumscribed hyperplasia, and type 3 glandular adenoma \[[@B3]\]. The size of BG hyperplasia lesions is up to 5 millimeters (mm) according to some sources and up to 10 mm according to other sources. Larger lesions were called BG hamartomas, adenomas, or brunneromas \[[@B3]--[@B6]\].

Proliferative lesions of BG account for 5-10% of all benign duodenal masses and less than 1% of all gastrointestinal tumours \[[@B1], [@B3], [@B6]\]. They are often identified incidentally during endoscopy \[[@B1], [@B7]\]. These lesions are considered benign; however, malignant cases have also been reported \[[@B1], [@B3]\].

The aetiology of these lesions has not yet been completely clarified \[[@B1], [@B8]\]. The suggested causes of these lesions include hyperchlorhydria and chronic local irritation,*Helicobacter pylori* (*H. pylori*) infection, chronic pancreatitis, and pancreatic exocrine insufficiency \[[@B1], [@B6]\].

The role of*H. pylori* infection in the pathogenesis of BG proliferative lesions remains unclear. This study examined the characteristics of the proliferative lesions of BG and examined their association with gastritis, duodenitis, and*H. pylori*.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

This retrospective study included patients who underwent an upper gastrointestinal system endoscopy in the endoscopy unit of our hospital during 2010--2015. A review of the patient records revealed that 3671 patients underwent an upper gastrointestinal system endoscopy due to dyspepsia, and stomach and duodenum biopsies were performed in 245 patients. Of these patients, a proliferative lesion of BG was identified in 18 patients. The age, gender, and histopathological findings in the biopsy samples of the gastric and duodenal mucosa; any presence of gastritis, duodenitis and*H. pylori* in the gastric mucosa; the type, size (mm), and the site of the proliferative lesion in BG; and the applied treatment methods were analysed \[[@B4], [@B6]\]. Clinical and pathological features of the patients with BG lesions were compared with 37 patients who had nonspecific duodenitis. Both groups were evaluated statistically.

2.2. Endoscopy and Biopsy Sampling {#sec2.2}
----------------------------------

Patient reports of the esophago-gastro-duodenoscopies (EGD) performed with Fujinon video endoscopy equipment (Model EG-250WR5, Tokyo, Japan) were reviewed and data were collected. The biopsy results of patients who had biopsies and polypectomies of lesions of the stomach and duodenal mucosa were checked ([Figure 1](#fig1){ref-type="fig"}).

2.3. Histopathological Examination {#sec2.3}
----------------------------------

Biopsy samples were fixed in 10% formalin for histological examination and then embedded in paraffin blocks. Serial sections of 4 *μ*m (microns) were prepared from these blocks. After deparaffinization, the tissue sections were stained with haematoxylin and eosin and Giemsa for histological examination and for identifying*H. pylori*, respectively. The slides were examined by a pathologist experienced in light microscopy.

Gastric and duodenal biopsy specimens were evaluated according to the updated Sydney system \[[@B9]\]. In the histological examination, the presence or absence of*H. pylori* was recorded as "yes" or "no", respectively, and the grading was recorded as "no*H. pylori*" or "mild", "moderate", or "severe*H. pylori***"** based on the updated Sydney system \[[@B10]\]. BG lesions were classified according to their size. Lesions with hamartoma less than 5 mm and lesions less than 5 mm were considered as hyperplasia \[[@B2]--[@B4]\] ([Figure 2](#fig2){ref-type="fig"}).

2.4. Statistical Analysis {#sec2.4}
-------------------------

The study data were analysed using licenced SPSS 21 package software (IBM Corp., Armonk, NY, USA). The Mann-Whitney U test was used to test the differences between the groups if data did not conform to a normal distribution. The Chi-square test was used to analyse the associations of the groups of nominal variables. If the nominal values were not sufficient in the cells of 2 × 2 tables, Fisher\'s exact test was used. The Pearson Chi-square (X^2^) test with Monte Carlo simulation was used to analyse r x c (row, column) tables. The results were interpreted at a significance level of 0.05. A level of*p* \< 0.05 indicated a significant difference, whereas*p* \> 0.05 indicated that there was no significant difference.

3. Results {#sec3}
==========

The female/male ratio of BG lesion patients included in the study was 1:1. The mean age of the patients was 48.6 years. The patients had chronic gastritis and chronic duodenitis at rates of 61.11 and 88.89%, respectively. The examinations revealed that 66.7% of the BG lesion patients had*H. pylori* in the gastric mucosa. The control group was nonspecific duodenitis patients with a female/male ratio of 2.4 and the mean age of the patients in this group was 39.4 years. In 43.2% of nonspecific duodenitis patients,*H. pylori* was found in the gastric mucosa. Patients with BG lesion had more*H. pylori* in gastric mucosa than patients with nonspecific duodenitis ([Table 1](#tab1){ref-type="table"}).

BG hyperplasia and hamartomas were found in 72.22 and 27.78% of the patients, respectively. The sections with BG hyperplasia had a diameter of 2--4 mm (with a mean diameter of 3 mm). BG hamartomas had a diameter between 5--30 mm (with a mean of 12.8 mm). Polypectomy was performed for BG hamartomas larger than 10 mm in order to eliminate the risk of bleeding and malignancy. Polypectomy was performed in three of the patients. No malignancies were diagnosed in the study patients. Yearly follow-ups with endoscopic examination were scheduled for the patients ([Table 2](#tab2){ref-type="table"}).

In our study, 61.54% of the cases of BG hyperplasia occurred in males; 80% of BG hamartomas were seen in women. However, no significant differences in gender were detected. In our study, there were statistically significant differences in the type and localization of the proliferative lesion of BG (*p* = 0.046). While BG hamartomas were most commonly found posteriorly, BG hyperplasia occurred in both aspects of the duodenum. A statistically significant difference was found between the type of the proliferative lesion and the age of the patients (*p* = 0.002). BG hamartomas are seen in advanced age. A statistically significant difference was found between the diameter and type of proliferative lesion (*p* = 0.0001). The mean lesion diameter of BG hamartomas was statistically significantly higher. However, there was not a statistically significant difference between the type of the proliferative lesion of BG and the other variables (*p* \> 0.05) ([Table 2](#tab2){ref-type="table"}).

Chronic gastritis and chronic duodenitis were found in 61.54 and 84.62% of patients, respectively. Chronic gastritis was present in 60% of the patients with BG hamartoma. Chronic duodenitis was found in all study patients. After duodenal biopsy, there was*H. pylori* in the gastric mucosa, and 66.7% of those had BG lesions; 49.63% of patients had non-BG lesions, such as nonspecific duodenitis and enteropathy.*H. pylori* was found in 69.23% of hyperplastic BGs.*H. pylori* density was mild or moderate in 22.2% and 77.8% of the patients with BG hyperplasia.*H. pylori* was detected in the stomach mucosa of 60% of patients with a BG hamartoma.*H. pylori* density was mild in 66.7% and moderate in 33.3% of these patients ([Figure 3](#fig3){ref-type="fig"}).

No recurrences were found during the scheduled yearly follow-ups in the patients who underwent a polypectomy. Eradication treatment was performed in patients with*H. pylori*. No pathological changes or signs of malignancy were found in the yearly routine endoscopic follow-ups in patients who were given treatment and underwent a diet for dyspepsia.

4. Discussion {#sec4}
=============

Most BGs are located proximal to the ampulla of Vater, decreasing in number towards the distal duodenum \[[@B1], [@B2]\]. BGs in submucosa contain cells secreting zymogens and mucus \[[@B10]\]. These glands allow for the neutralization of chyme (i.e., the mixture of food and acid coming from the stomach) by secreting approximately 200 milliliters of an alkaline mucus (with a pH between 8.1--9.3) daily \[[@B5], [@B11]\]. BGs secrete pepsinogen, urogastrone, and enterokinase \[[@B11]\].

Feyrter classified the abnormal proliferation of BGs in 1934. According to this classification, multiple areas of sessile nodular hyperplasia along the duodenum are named as type 1, sessile nodular hyperplasia in the duodenal bulbus are named as type 2, and polypoid tumour-like glandular adenomas are named as type 3 \[[@B1], [@B3], [@B12]\]. The most common form is type 2 \[[@B3]\].

BG hyperplasia consists of many small polypoid lesions of excessive BG separated by fibrous septa. A BG hamartoma consists of a single mass that contains a mixture of acini, channels, smooth muscle, adipose tissue and lymphoid tissue \[[@B4], [@B6]\]. Pathologists believe that these lesions are caused by the same pathological process \[[@B4], [@B11], [@B12]\]. BG hamartomas today are not called BG adenomas because they do not show cellular atypia \[[@B3], [@B4]\]. Researchers classify lesions smaller than either 5 or 10 mm as BG hyperplasia and larger lesions as hamartomas \[[@B4], [@B12], [@B13]\]. We applied this classification to our study.

In various patients with routine EGDs, BG hyperplasia was found in 0.3% of the sample \[[@B14]\]. In EGD series, 2.2--7.6% of duodenal biopsies were diagnosed with BG hyperplasia \[[@B7], [@B12]--[@B14]\]. They usually occur as multiple small nodular lesions in the first part of the duodenum \[[@B3]\], with a cobblestone appearance on the mucosa \[[@B3], [@B6]\]. Hyperplastic BGs generally display an equal gender distribution and are seen at around 50 years of age \[[@B1], [@B6]\]. However, some studies report a higher incidence in men \[[@B12]\]. The major complaint of the patients with hyperplastic BGs is dyspepsia \[[@B3], [@B6]\].

BG hamartomas are found in 0.01--0.07% of routine EGD patients \[[@B14]--[@B16]\]. They constitute 5--10% of benign duodenal masses \[[@B17]--[@B20]\]. They are generally seen in the posterior wall of the first part of the duodenum and are solitary (57--70%) \[[@B4], [@B8], [@B20], [@B21]\]. They may vary in size between 0.5 and 12 cm. They appear in the shape of polyps with a stalk in 88 to 89% of the cases, and 11 to 12% of them appear as sessile polyps \[[@B8], [@B21]\]. The age range is 15--80, with a usual occurrence in the fifth decade \[[@B4], [@B8], [@B21]\]. In some studies, they were found to be more common in men and in others they were found to be more common in women \[[@B4], [@B8], [@B21]\]. Of the symptomatic patients, 28--61% may present with gastrointestinal haemorrhage, 51% with abdominal pain, and 44--50% with nausea and vomiting. Rarely there are signs of intestinal obstruction, duodenal intussusception, obstructive jaundice, or recurrent pancreatitis \[[@B1], [@B20], [@B21]\].

In our study, BG hyperplasia was found in 0.35% of all patients who underwent EGDs and in 5.3% of the patients who underwent duodenal biopsies. The mean age of the patients was 40.9 years. The female/male ratio was 0.6. The mean diameter of the lesions was 3 mm, and they were mostly located in the bulb. BG hamartomas were found in 0.13% of the patients who underwent EGD and in 2% of the patients from whom duodenal biopsy specimens were collected. The mean age of the patients was 68.6 years. The female/male ratio was 4. The mean diameter of the lesions was 12.8 mm, and the lesions were most commonly located at the posterior duodenum. All patients presented with nonspecific complaints.

Diagnosis is usually confirmed by imaging studies and EGD \[[@B1]\]. Endoscopy, abdominal tomography, endoscopic sonography, barium X-rays, fluoroscopic examination, and transabdominal sonography are used as diagnostic tests \[[@B20]--[@B22]\]. Proliferative lesions of BG are usually considered as benign \[[@B12], [@B14]\]. However, some studies reported epithelial dysplasia or adenocarcinomas \[[@B1], [@B13], [@B23]\]. In our study, dysplasia and malignancy were not detected in the lesions.

Differential diagnosis for these lesions includes adenomatous polyps, lipomas, leiomyomas, lymphomas, ectopic pancreatic tissue, gastrointestinal tumours, etc. \[[@B21], [@B22]\]. In proliferative lesions of BG, conservative treatments may be administered, accompanied with regular follow-ups using endoscopy \[[@B20], [@B21]\]. The endoscopic removal of BG hamartomas should be considered to establish a definitive diagnosis and to prevent potential complications, including bleeding or obstruction \[[@B21], [@B22]\]. Surgery is recommended in patients with wider pedunculated or sessile BG hamartomas, in patients with unsuccessful endoscopic interventions and in patients in whom a malignancy is suspected \[[@B24], [@B25]\]. In our study, no surgical intervention was needed.

The pathogenesis of proliferative lesions of BGs has not yet been completely elucidated \[[@B1]\]. The main aetiology is suggested to be a chronic local irritation in the duodenal mucosa \[[@B26]\]. The major factors studied in mucosal injury are gastric hyperacidity, mechanical stimuli in the duodenum and*H. pylori* infections \[[@B26], [@B27]\]. It has been reported that BG hyperplasia especially develops in patients with chronic gastritis and duodenal ulcers in the presence of hyperchlorhydria \[[@B13], [@B20]\]. BG hyperplasia has been reported to present comorbidly with peptic ulcers, chronic renal failure and chronic pancreatitis \[[@B20], [@B26], [@B28]\]. However, this opinion has not been widely accepted either.

*H. pylori* is the major cause of several gastroduodenal diseases, including chronic gastritis, duodenitis and duodenal ulcers \[[@B29]\]. Studies have found that gastric non-Hodgkin lymphoma formation was involved in the etiology of*H. pylori,* especially in the formation of esophageal and gastric cancer \[[@B30], [@B31]\].*H. pylori* eradication therapy was found to decrease the risk of malignancy \[[@B30], [@B31]\]. However, the role of*H. pylori* in the etiology of rare duodenal malignancies remains unclear \[[@B31]\]. It has been suggested that*H. pylori* infection may be involved in the pathogenesis of BG hyperplasia \[[@B1], [@B32]\]. Studies have reported that*H. pylori* was detected in 71% of the patients with BG hamartomas and that*H. pylori* may induce proliferative processes in BGs. It has also been reported that*H. pylori* infections and chronic gastritis may induce the progression of a hyperplastic lesion to a hamartoma \[[@B33], [@B34]\]. There are also other reports that do not address*H. pylori* in the aetiology of these lesions or state that it was not associated with these type of lesions \[[@B4], [@B12], [@B20]\].

In our study, 61.11% of the patients had chronic gastritis, 88.89% had chronic duodenitis and 66.7% had*H. pylori* in the gastric mucosa.*H. pylori* was detected in BG hamartomas and hyperplastic BGs in our study at rates of 60 and 69.2%, respectively. This suggests that*H. pylori* may play an important role in the aetiology of BG proliferative lesions due to the chronic local irritation associated with both chronic gastritis and chronic duodenitis.

5. Conclusions {#sec5}
==============

BG hyperplasia and hamartomas are usually rare benign duodenal lesions that are detected incidentally. The pathogenesis of these lesions is still unclear. Several investigators have suggested a variety of causal factors. In our study, we found that BG hyperplasia and hamartomas were associated with a high rate of chronic gastritis, chronic duodenitis, and the presence of*H. pylori*. We are of the opinion that*H. pylori* should be considered in the pathogenesis and treatment of BG hyperplasia and hamartomas.
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###### 

Distribution of clinical and pathological features.

  ------------------------------------ -------------------- --------------------- -------------------- -------- ----------- -----------
  Clinical and pathological features   Control Group        BG ^a^ Lesion Group   Statistical result                        

  (Nonspecific duodenitis)                                                                                                  

  n                                    \%                   n                     \%                   *p*                  

                                                                                                                            

  Gender                               Female               26                    70.3                 9        50          0,208 ^b^

  Male                                 11                   29.7                  9                    50                   

  Gastritis Status                     Chronic gastritis    19                    51.4                 11       61.1        0,49 ^b^

  Active chronic gastritis             18                   48.6                  7                    38.9                 

  Duodenitis\                          Chronic duodenitis   37                    100                  16       88.9        0.103 ^c^
  Status                                                                                                                    

  Active chronic duodenitis            0                    0                     2                    11.1                 

  *H. pylori* ^f^ Status               No                   21                    56.8                 6        33.3        0,103 ^b^

  Yes                                  16                   43.2                  12                   66.7                 

                                                                                                                            

  Variable                                                  n Mean Min.           Max.                 SD ^e^               

                                                                                                                            

  Age                                  Control Group        37 39.4 14            71                   15,3     0,086 ^d^   

  BG Lesion Group                      18 48.6 16           85                    18,3                                      
  ------------------------------------ -------------------- --------------------- -------------------- -------- ----------- -----------

^a^BG = Brunner\'s gland, ^b^ X^2^ = Chi-square test, ^c^ f = Fisher\'s exact test, ^d^ U = Mann-Whitney U test, ^e^ SD = standard deviation, and ^f^ *H. pylori*= *Helicobacter pylori*.

###### 

Association between the proliferative lesions of Brunner\'s gland and the variables.

  ---------------------------------------- -------------------------------------------- ---------------------------------------- ------------ --------- ------------ -----------
  Variables                                Type of the Proliferative Lesion of BG ^a^   Statistical result                                                           

  Hamartoma                                Hyperplasia                                                                                                               

  *n*                                      \%                                           *n*                                      \%           *p* ^b^                

                                                                                                                                                                     

  Gender                                   Female                                       4                                        80           5         38.46        0.294

  Male                                     1                                            20                                       8            61.54                  

  Gastritis Status                         Chronic gastritis                            3                                        60           8         61.54        0.676

  Active chronic gastritis                 2                                            40                                       5            38.46                  

  Lymphoid Hyperplasia                     No                                           3                                        60           11        84.62        0.533

  Yes                                      2                                            40                                       2            15.38                  

  Foveolar Hyperplasia                     No                                           5                                        100          12        92.31        0.722

  Yes                                      0                                            0                                        1            7.69                   

  Gastric Mucosa Inflammation              No                                           0                                        0            0         0            \-

  Yes                                      5                                            100                                      13           100                    

  Gastric Mucosa Activation                No                                           3                                        60           6         46.15        0.5

  Yes                                      2                                            40                                       7            53.85                  

  Gastric Mucosa Metaplasia                No                                           4                                        80           13        100          0.278

  Yes                                      1                                            20                                       0            0                      

  Gastric Mucosa Atrophy                   No                                           4                                        80           13        100          0.278

  Yes                                      1                                            20                                       0            0                      

  Gastric Mucosa *H. pylori* ^d^           No                                           2                                        40           4         30.77        0.561

  Yes                                      3                                            60                                       9            69.23                  

  Duodenitis\                              Chronic duodenitis                           5                                        100          11        84.62        0.51
  Status                                                                                                                                                             

  Active chronic duodenitis                0                                            0                                        2            15.38                  

  Site of the Proliferative Lesion of BG   Anterior bulbus                              4                                        80           3         23.08        **0.046**

  Posterior bulbus                         1                                            20                                       2            15.38                  

  On both sides                            0                                            0                                        8            61.54                  

                                                                                                                                                                     

  Variables                                                                             Type of the Proliferative Lesion of BG                                       

  *n*                                      Mean Min. Max.                               SD ^e^                                   *p* ^c^                             

                                                                                                                                                                     

  Age                                      BG hamartoma                                 5                                        68.6 52 85   11.93     **0.002**    

  BG hyperplasia                           13                                           40.92 16 63                              13.97                               

  Lesion diameter (mm)                     BG hamartoma                                 5                                        12.8 5 30    9.88      **0.0001**   

  BG hyperplasia                           13                                           3.07 2 4                                 0.8                                 
  ---------------------------------------- -------------------------------------------- ---------------------------------------- ------------ --------- ------------ -----------

^a^ BG = Brunner\'s gland, ^b^ f = Fisher\'s exact test, ^c^ U = Mann-Whitney U test, ^d^ *H. pylori* = *Helicobacter pylori*, and ^e^ SD = standard deviation.
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